Volume 88, Issue 1 pp. 21-27
Cancer Cell Biology

Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas

Tetsuro Sameshima

Corresponding Author

Tetsuro Sameshima

Department of Neurosurgery, Miyazaki Medical College, Kiyotake, Miyazaki, Japan

Department of Neurosurgery, Miyazaki Medical College, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. Fax: (81)-985-84-4571Search for more papers by this author
Kazuki Nabeshima

Kazuki Nabeshima

Department of Pathology, Miyazaki Medical College, Kiyotake, Miyazaki, Japan

Search for more papers by this author
Bryan P. Toole

Bryan P. Toole

Department of Anatomy and Cellular Biology, Tufts University School of Medicine, Boston, Massachusetts, USA

Search for more papers by this author
Kiyotaka Yokogami

Kiyotaka Yokogami

Department of Neurosurgery, Miyazaki Medical College, Kiyotake, Miyazaki, Japan

Search for more papers by this author
Yasunori Okada

Yasunori Okada

Department of Pathology, Keio University School of Medicine, Tokyo, Japan

Search for more papers by this author
Tomokazu Goya

Tomokazu Goya

Department of Neurosurgery, Miyazaki Medical College, Kiyotake, Miyazaki, Japan

Search for more papers by this author
Masashi Koono

Masashi Koono

Department of Pathology, Miyazaki Medical College, Kiyotake, Miyazaki, Japan

Search for more papers by this author
Shinichiro Wakisaka

Shinichiro Wakisaka

Department of Neurosurgery, Miyazaki Medical College, Kiyotake, Miyazaki, Japan

Search for more papers by this author

Abstract

EMMPRIN (extracellular matrix metalloproteinase inducer), also called CD147, basigin or M6 in the human, is a member of the immunoglobulin superfamily that is present on the surface of tumor cells and stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPs). In our study, we investigated expression of EMMPRIN in human normal brain and gliomas, since mouse basigin and chicken HT7, the species homologues of human EMMPRIN, are associated with neuronal interactions and normal blood-brain barrier function, respectively. EMMPRIN expression was detected in all samples of non-neoplastic brain and glioma tissues examined. However, expression levels of EMMPRIN mRNA and protein were significantly higher in gliomas than in non-neoplastic brain. Moreover, levels of mRNA expression and immunohistochemical staining correlated with tumor progression in gliomas: They were highest in the most malignant form of glioma, glioblastoma multiforme, followed by anaplastic astrocytoma and then low-grade astrocytoma. Also, immunolocalization revealed quite different distributions in non-neoplastic brain and glioma: EMMPRIN was demonstrated only in vascular endothelium in non-neoplastic regions of the brain, whereas it was present in tumor cells but not in proliferating blood vessels in malignant gliomas. These data indicate that an MMP inducer molecule EMMPRIN is differently expressed in human normal brain and gliomas and could be associated with astrocytoma progression. Possible mechanisms whereby glioma cell EMMPRIN could influence tumor progression will be discussed. Int. J. Cancer 88:21–27, 2000. © 2000 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.